Sanofi stays “on track” with US OTC switch plans

28 April 2020 - Deborah Wilkes

Premium

Sanofi Consumer Healthcare’s development plans for switching Cialis (tadalafil) and Tamiflu (oseltamivir) from prescription-to-OTC status in the US remain “on track”, according to Paul Hudson, Sanofi’s chief executive officer.

Click tags below for more information on topics:

Sanofi Consumer Healthcare

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: